Some love for CTIX: http://www.rttnews.com/2651
Post# of 72440
Posted On: 05/22/2016 8:41:45 AM
Re: daydreaming2 #22729
Some love for CTIX:
http://www.rttnews.com/2651715/now-is-the-tim...-ctix.aspx
Now Is The Time To Keep An Eye On CTIX...
5/22/2016 2:23 AM ET
Shares of Cellceutix Corp. (CTIX.OB) have gained over 24% year-to-date, and the impending results from the company's phase II trial of Prurisol for psoriasis can have a significant impact on the stock price.
Prurisol, Cellceutix's anti-psoriasis drug candidate, acts through immune modulation and PRINS (psoriasis-associated RNA inducted by stress) reduction. This drug candidate is being developed under 505(b)(2) regulatory pathway because Prurisol is an ester of FDA-approved Abacavir, an antiviral medication, marketed as Ziagen.
The 505(b)(2) regulatory pathway can help expedite a drug's approval by relying, in part, on clinical data from an already approved drug.
A phase II clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is underway, and top line results are expected this month. The results will include data from one placebo arm and three oral dosing regimens of Prurisol.
If the company has been able to keep the deadline, then the phase II trial data would have been unblinded last week (week ending May 22nd, 2016). Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
Will the phase II psoriasis trial produce itching results leaving investors scratching their heads or will the data be soothing enough to lift investors' spirits? Stay tuned...
CTIX.OB closed Friday's trading at $1.64, down 1.09%.
by RTT Staff Writer
http://www.rttnews.com/2651715/now-is-the-tim...-ctix.aspx
Now Is The Time To Keep An Eye On CTIX...
5/22/2016 2:23 AM ET
Shares of Cellceutix Corp. (CTIX.OB) have gained over 24% year-to-date, and the impending results from the company's phase II trial of Prurisol for psoriasis can have a significant impact on the stock price.
Prurisol, Cellceutix's anti-psoriasis drug candidate, acts through immune modulation and PRINS (psoriasis-associated RNA inducted by stress) reduction. This drug candidate is being developed under 505(b)(2) regulatory pathway because Prurisol is an ester of FDA-approved Abacavir, an antiviral medication, marketed as Ziagen.
The 505(b)(2) regulatory pathway can help expedite a drug's approval by relying, in part, on clinical data from an already approved drug.
A phase II clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is underway, and top line results are expected this month. The results will include data from one placebo arm and three oral dosing regimens of Prurisol.
If the company has been able to keep the deadline, then the phase II trial data would have been unblinded last week (week ending May 22nd, 2016). Cellceutix expects to release top-line data from the study approximately one week after the blind is removed.
Will the phase II psoriasis trial produce itching results leaving investors scratching their heads or will the data be soothing enough to lift investors' spirits? Stay tuned...
CTIX.OB closed Friday's trading at $1.64, down 1.09%.
by RTT Staff Writer
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼